discovered that the gene signatures of CD8+ TRM cells in triple-negative breast cancer patients are significantly associated with their response to pembrolizumab, highlighting the critical role of these cells in maintaining long-term anti-tumor immunity and their potential as targets for breast cancer vaccines (69). This evidence concerns the gene CD8A and breast carcinoma.